8-K 1 a03-5118_18k.htm 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 10, 2003

 

Savient Pharmaceuticals, Inc.

(Exact name of issuer as specified in its charter)

 

Delaware

 

 

0-15313

 

 

13-3033811

(State or Other Jurisdiction
of Incorporation)

 

 

(Commission File Number)

 

 

(IRS Employer
Identification No.)

 

 

One Tower Center, 14th Floor
East Brunswick, New Jersey

08816

 

 

(Address of Principal Executive Offices)

(Zip Code)

 

 

Registrant’s telephone number, including area code: (732) 418-9300

 

 

 

 

 

None.

(Former Name or Former Address, if Changed Since Last Report.)

 

 

 

ITEM 7.                                                     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

 

 

(c)                                  Exhibits.

 

99.1               Press release issued by Savient Pharmaceuticals, Inc. (the “Company”) on November 10, 2003.

 

ITEM 12.                                               RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

On November 10, 2003, the Company announced its financial results for the three and nine months ended September 30, 2003.  A copy of the Company’s press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SAVIENT PHARMACEUTICALS, INC.

 

(Registrant)

 

 

 

 

 

By:

  /s/ Whitney K. Stearns, Jr.

 

 

 

Whitney K. Stearns, Jr.

 

 

Senior Vice President—Chief Financial Officer and
Treasurer

 

 

Dated: November 10, 2003

 

3